FGFR2 overexpression via immunohistochemistry (IHC) is observed in 31–61% of gastric cancer cases and correlates with aggressive tumor characteristics such as advanced T stage, increased lymph node metastasis, and reduced overall survival rates, highlighting its potential as a therapeutic target [13,14,15]. Here, FGFR2 is linked to gastric cancer.